Mila and SEVO Bioscience, a startup specializing in the development of biomolecules, vaccines, and sustainable biological products using genetically engineered microalgae, have forged a partnership to bolster synthetic biology development.
This strategic collaboration will enable SEVO Bioscience to leverage Mila’s multidisciplinary artificial intelligence, modelling, and complex data processing, while also gaining access to professional development opportunities, events, high-level knowledge sharing, and a globally recognized innovation hub.
Through this partnership, SEVO Bioscience also launched its research project, the “Synthetic Trait Identifier and Assembler” (SYNTIA). With Mila’s support, SEVO Bioscience will advance SYNTIA, an AI-driven protein design platform that integrates synthetic biology and machine learning to engineer proteins optimized beyond natural biological limits, which could have a significant impact on the production of high-value specialty products.
This partnership highlights the growing role of enterprise AI as a core driver of innovation in highly complex and regulated industries. By applying advanced machine learning and modelling to protein design and synthetic biology, the collaboration demonstrates how AI is moving beyond decision support to directly enable the creation of novel, high-value biological assets. The SYNTIA platform illustrates how AI can be embedded into R&D workflows to generate proprietary intellectual property and accelerate product development at scale.
More broadly, the collaboration reflects a wider shift toward AI-native platforms that integrate complex data, scientific expertise, and sustainable production models. The initiative underscores how enterprise AI is increasingly being deployed to tackle mission-critical challenges, support resilient and sustainable manufacturing, and unlock new commercial opportunities across the life sciences.
Stéphane Létourneau, Executive Vice-President of Mila, said: “This partnership reflects a shared commitment to responsible and innovative applied research in the field of biotechnology. By combining SEVO Bioscience’s work in engineered microalgae with Mila’s expertise in AI, we aim to push the boundaries of biological understanding and accelerate the development of high-impact, practical solutions.”
Dilan B. Jaunky, Chief Executive Officer of SEVO Bioscience, said: “This partnership opens an entirely new way of accessing biology. We’re excited to collaborate with the exceptional talent and expertise at Mila and look forward to building the next generation of AI-driven biological solutions together.”